R Squared Ltd Invests $103,000 in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

R Squared Ltd purchased a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the 4th quarter, HoldingsChannel reports. The fund purchased 2,460 shares of the biopharmaceutical company’s stock, valued at approximately $103,000.

A number of other large investors have also recently bought and sold shares of the stock. KBC Group NV lifted its holdings in shares of Ultragenyx Pharmaceutical by 2,275.8% during the fourth quarter. KBC Group NV now owns 61,010 shares of the biopharmaceutical company’s stock valued at $2,567,000 after acquiring an additional 58,442 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in Ultragenyx Pharmaceutical by 1.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock valued at $928,000 after purchasing an additional 294 shares during the last quarter. Nordea Investment Management AB lifted its holdings in Ultragenyx Pharmaceutical by 8.9% during the 4th quarter. Nordea Investment Management AB now owns 39,673 shares of the biopharmaceutical company’s stock valued at $1,658,000 after purchasing an additional 3,246 shares during the last quarter. Principal Financial Group Inc. boosted its position in Ultragenyx Pharmaceutical by 740.0% in the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock valued at $4,802,000 after buying an additional 76,150 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in Ultragenyx Pharmaceutical during the third quarter worth about $83,000. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock opened at $43.40 on Friday. The firm’s 50 day moving average price is $44.37 and its two-hundred day moving average price is $49.56. Ultragenyx Pharmaceutical Inc. has a 52-week low of $37.02 and a 52-week high of $60.37. The stock has a market cap of $4.01 billion, a PE ratio of -6.71 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The business had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. During the same period last year, the company earned ($2.23) EPS. The firm’s revenue was up 42.3% on a year-over-year basis. As a group, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RARE has been the subject of a number of research analyst reports. TD Cowen lifted their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Canaccord Genuity Group reiterated a “buy” rating and issued a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. Wells Fargo & Company increased their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a report on Friday, December 20th. JPMorgan Chase & Co. cut their price target on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, November 21st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.43.

Insiders Place Their Bets

In related news, CEO Emil D. Kakkis sold 11,727 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $42.23, for a total value of $495,231.21. Following the sale, the chief executive officer now directly owns 2,183,985 shares in the company, valued at $92,229,686.55. This trade represents a 0.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.